GAVI R

1
GAVI RD projects

• 3 vaccines against 3 pathogens meningococcus,
  pneumococcus, rotavirus
• 3 technologies - to decrease dependance on cold
  chain, - to eliminate the use of sharps, - to
  develop tools to measure vaccine coverage
• Management structure proposed for the ADIPs
• Mechanisms for the opening of Window 3 of the
  vaccine fund

2
(No Transcript)
3
Outline of the guidelines developed by the RD
Task Force for opening Window 3 of the Vaccine
Fund

• The revised paper addresses
• Financial complementarity of Window 3 with other
  support
• Types of activities to be supported
• Undertaking of commercial negotiations to achieve
  a quid pro quo, when relevant
• Avoidance of conflict of interest in selection of
  activities
• Methods to transfer support from the Vaccine Fund
• Possible future purchase of products by the
  Vaccine Fund

4
Financial complementarity of Window 3 with other
support

• Window 3 funding will serve as an advocacy tool
  in two distinct ways
• Financial support from the Vaccine Fund will
  encourage potential partners to invest directly
  in GAVI supported RD activities.
• Prospective donors will be able to channel their
  contributions through the Vaccine Fund.

5
Types of activities to be supported

• The prioritized tasks and activities supported by
  Window 3 are integral components of the
  Accelerated Development Introduction Plans
  (ADIPS) for vaccines specifically targeted by the
  GAVI Board, expanding to include future vaccine
  technologies. Initially, these will be
• epidemiologic measurements of the burden of
  disease
• clinical trials that assess the safety,
  immunogenicity, practicality, efficacy and
  effectiveness of the vaccines

6
Undertaking of commercial negotiations to achieve
a quid pro quo, when relevant

• Wherever possible, multiple manufacturers engaged
  as partners
• Transparent funding, allowing all firms to
  respond to requests for proposals
• Funding focused on activities with minimal direct
  licensing benefits in industrial country markets
• Request for appropriate returns to the public
  sector

7
Avoidance of conflict of interest in selection of
activities

• Experts from industry will not serve as members
  of the Independent Review Panels when studies of
  specific products are to be considered
• All members of the Independent Review Panels will
  fill out a form in which they must declare equity
  holdings, paid consultancies, collaborations,
  etc.

8
Methods to transfer support from the Vaccine Fund

• An funding envelope (allocated on a semi-annual
  or annual basis) to be disbursed to the ADIP
  team.
• A Steering Group (accountable to the Board) to
  provide oversight to the ADIP team, its plan,
  budget and progress toward ADIP milestones. The
  Steering Group would authorize use of the funds
  by the ADIP team.

9
Possible future purchase of products by the
Vaccine Fund

• Any decision on purchase of new vaccines or
  related products by the Vaccine Fund to take
  place through the same process as exists for
  other vaccines.
• Situations where some level of future guaranteed
  purchase is required to be brought to the GAVI
  Board on an individual case basis.